Financial Highlights

PROFIT AND LOSS METRICS

Net Sales (INR Mn)
Net Sales
Dividend Per Share (INR)
Dividend Per Share
Ebitda (INR Mn)
Ebitda
Net Profit before exceptional items (INR Mn)
Net Profit
Profit Before Tax before exceptional items (INR Mn)
Profit Before Tax
Total Investment In R&D (INR Mn)
Total Investment In R&D

BALANCE SHEET METRICS

Net Debt To Equity Ratio
Net Debt To Equity Ratio
Capital Employed (INR Mn)
Capital Employed

6th Rank

in the Indian
Pharma Market

3rd Rank

by Prescriptions
in USA

11 Brands

among the top 300 in the
Indian Pharma Market

Financial
Capital

Financial Capital
EBITDA
18.1%
of Sales
Net-Debt Equity
0.05:1
Dividend
325%

Manufacturing
Capital

Manufacturing Capital
Number of
US FDA Inspected
Manufacturing Units 13
Number of
Manufacturing
Sites
15
Total Capital Expenditure
(INR Mn) in
FY 2020-21
6,276

Intellectual
Capital

Intellectual Capital
Total
Active
Patents
886
New Products
Launched in
FY 2020-21 in US
15
Received Approval
for ANDAs
for US
19

Natural
Capital

Natural Capital
Energy from
Renewable Sources 12.2% of total energy consumption
Water
Recycled
742,179 Kl
GHG Emissions
Saved 9,775 tCO2e

Human
Capital

Human Capital
Expenditure on
Employee Benefits
(INR Mn)
28,259
Female
Representation
at Board Level
36% in India as on
31 March, 2021
Learning and
Development Expenditure
(India)
INR 7.5 Million

Social and
Relationship
Capital

Social and Relationship Capital
Total
Expenditure
INR 298 Million
Total Number
of Beneficiaries
1,483,657
Provision of Health and
Safety Equipment for
COVID-19
2.0 Million+